AI
ABMD

Analytic Investors’s Abiomed Inc ABMD Stock Holding History

Analytic Investors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-9,695
Closed -$637K – 646
2015
Q2 		$637K Buy
+9,695
New +$644K 0.01% 435

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Analytic Investors's ABMD Position: Q3 2015 in Review

Analytic Investors sold out of Abiomed Inc (ABMD) in Q3 2015, closing a stake of 9,695 shares — an estimated $637K sold.

Analytic Investors first reported a position in ABMD in Q2 2015 and held it in 1 quarter. The position peaked at $637K in Q2 2015. 243 funds tracked by Wall St. Rank hold ABMD as of Q3 2015.

  • Analytic Investors reported no remaining Abiomed Inc position as of Q3 2015 after selling out during the quarter.
  • Analytic Investors sold 9,695 Abiomed Inc shares in Q3 2015, an estimated $637K.
  • Analytic Investors first reported a position in Abiomed Inc in Q2 2015 and held it in 1 quarter.
  • Analytic Investors's Abiomed Inc position peaked at $637K in Q2 2015.
  • 243 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2015.

Based on Analytic Investors's 13F filing for Q3 2015, filed 12 Nov 2015.